Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

263
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
263
Bioavailability Study Design: Single Versus Multiple Dose Studies01:11

Bioavailability Study Design: Single Versus Multiple Dose Studies

78
Bioavailability studies are essential for understanding how a drug is absorbed, distributed, metabolized, and excreted in the body. These studies assess the extent and rate at which the active pharmaceutical agent becomes available at the site of action. The design of bioavailability studies can involve single-dose or multiple-dose regimens, each with distinct advantages and limitations.Single-dose studies are the preferred approach due to their simplicity and reduced drug exposure for...
78
Dose Size and Dosing Frequency: Determination Methods01:21

Dose Size and Dosing Frequency: Determination Methods

96
Determining the optimal dose size and dosing frequency in pharmacotherapy is crucial for achieving therapeutic effectiveness while minimizing adverse effects. This article explores the methodologies employed in determining these parameters, focusing on their significance and interplay to tailor dosing regimens.Dose Size: Dose size refers to the amount of a drug administered in a single dose. It is determined based on the drug's pharmacodynamics and pharmacokinetics properties and...
96
Dosage Regimens: Partial Pharmacokinetic Parameters01:01

Dosage Regimens: Partial Pharmacokinetic Parameters

54
It is not uncommon for complete drug pharmacokinetic profiles to remain elusive in pharmacokinetics. This necessitates certain educated assumptions by pharmacokineticists to determine appropriate dosage regimens without comprehensive pharmacokinetic data from animal or human studies. One prevalent assumption is setting the bioavailability factor, denoted as F, to 1 or 100%. This assumption caters to the scenario where a drug doesn't achieve full systemic absorption, resulting in the patient...
54
Bioequivalence Data: Statistical Interpretation01:16

Bioequivalence Data: Statistical Interpretation

70
Body:The statistical interpretation of bioequivalence data is a significant aspect of pharmaceutical research. Bioequivalence refers to the absence of any significant difference in the rate and extent to which the active ingredient in pharmaceutical products becomes available at the site of drug action when administered at the same molar dose under similar conditions. This helps determine if different drug products have similar absorption rates, ensuring their interchangeability.Statistical...
70
Dosage Regimens: Designs and Approaches01:28

Dosage Regimens: Designs and Approaches

116
Designing a dosage regimen, which refers to the manner of drug administration, is a complex process involving the selection of drug dose, route, and frequency. This process is underpinned by pharmacokinetic parameters derived from tests and population averages. These parameters are then tailored to patient-specific variables such as diagnosis, demographics, and allergy status. Once therapy commences, therapeutic response monitoring is critical and achieved through clinical and physical...
116

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

PS-SAM: propensity-score-integrated self-adapting mixture prior to dynamically and efficiently borrow information from historical data.

Journal of biopharmaceutical statistics·2025
Same author

A Bayesian phase II proof-of-concept design for clinical trials with longitudinal endpoints.

Statistics in medicine·2023
Same author

A confirmatory basket design considering non-inferiority and superiority testing.

Journal of biopharmaceutical statistics·2023
Same author

Burden of cystic fibrosis in children <12 years of age prior to the introduction of CFTR modulator therapies.

BMJ open respiratory research·2021
Same author

Design and analysis of drop-the-losers studies using binary endpoints in the rare disease setting.

Journal of biopharmaceutical statistics·2021
Same author

Bayesian additive decision trees of biomarker by treatment interactions for predictive biomarker detection and subgroup identification.

Journal of biopharmaceutical statistics·2017
Same journal

Development of a Biphasic Modified-Release Ibuprofen Tablet Formulation: Single-Dose and Multiple-Dose Pharmacokinetics and Food-Effect Studies.

Clinical and translational science·2026
Same journal

Circulating M-MDSC Expansion During Therapy Associates With Treatment Response in Multiple Myeloma: A Longitudinal Observational Study.

Clinical and translational science·2026
Same journal

PBPK Modeling and Clinical Data Reveal Reduced Impact of CYP3A4 and CYP2C9 Inhibitors on Elimination of Siponimod.

Clinical and translational science·2026
Same journal

Drug Interactions of Vebreltinib, a Novel Type I c-Met Inhibitor, Coadministration With Rifampin or Itraconazole in Healthy Participants.

Clinical and translational science·2026
Same journal

Correction to "Severe Thiopurine-Induced Myelosuppression in a Pediatric Acute Lymphoblastic Leukemia Patient ith the NUDT15 *1/*6 Genotype: A Brief Report".

Clinical and translational science·2026
Same journal

Model-Informed Development of a Subcutaneous Formulation of Tislelizumab: Phase 1 Pharmacokinetics in Patients With Cancer.

Clinical and translational science·2026
See all related articles

Related Experiment Video

Updated: Nov 15, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K

Beyond exposure-response: A tutorial on statistical considerations in dose-ranging studies.

Glen Laird1, Lei Xu1, Meng Liu1

  • 1Vertex Pharmaceuticals Incorporated, Boston, Massachusetts, USA.

Clinical and Translational Science
|March 2, 2021
PubMed
Summary
This summary is machine-generated.

Designing effective dose-ranging studies is vital for phase II drug development. This tutorial covers key statistical principles and methods to avoid costly errors in drug development.

More Related Videos

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.1K
Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities
06:51

Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities

Published on: February 20, 2021

5.3K

Related Experiment Videos

Last Updated: Nov 15, 2025

Irradiator Commissioning and Dosimetry for Assessment of LQ &#945; and &#946; Parameters, Radiation Dosing Schema, and in vivo Dose Deposition
06:20

Irradiator Commissioning and Dosimetry for Assessment of LQ α and β Parameters, Radiation Dosing Schema, and in vivo Dose Deposition

Published on: March 11, 2021

7.5K
Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation
10:33

Expedited Radiation Biodosimetry by Automated Dicentric Chromosome Identification ADCI and Dose Estimation

Published on: September 4, 2017

16.1K
Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities
06:51

Dosimetry for Cell Irradiation using Orthovoltage 40-300 kV X-Ray Facilities

Published on: February 20, 2021

5.3K

Area of Science:

  • Pharmacometrics
  • Clinical Trial Design
  • Biostatistics

Background:

  • Dose-ranging studies are essential in Phase II drug development.
  • They provide critical data that complements exposure-response analyses.
  • Statistical design challenges in these studies can lead to significant development costs.

Purpose of the Study:

  • To review five key statistical principles for designing effective dose-ranging studies.
  • To describe common statistical approaches used in dose-ranging study design.
  • To enhance understanding of statistical design issues in early drug development.

Main Methods:

  • Review of fundamental statistical principles for study design.
  • Description of pairwise comparison methods.
  • Explanation of modeling approaches, including Multiple Comparison Procedure modeling.

Main Results:

  • Identification of five core statistical principles for robust study design.
  • Illustrative examples of statistical approaches applied to dose-ranging studies.
  • Guidance on selecting appropriate statistical methods based on study objectives.

Conclusions:

  • Proper statistical design of dose-ranging studies is critical for efficient drug development.
  • Understanding and applying key statistical principles can mitigate risks and costs.
  • This tutorial provides a framework for designing statistically sound dose-ranging studies.